AZ’s drug reduces risk of symptomatic COVID by 77%
AstraZeneca said on Friday its monoclonal antibody drug AZD7442 reduces the risk of developing symptomatic case of COVID-19 by 77%.
A pre-exposure prophylaxis trial that included 5,197 participants showed that there were no severe coronavirus cases or deaths among those who received the drug, while three severe cases, two of which resulted in death, occurred within the placebo group. “We are very encouraged by these efficacy and safety data in high-risk people, showing our long-acting antibody combination has the potential to protect from symptomatic and severe disease, alongside vaccines,” said Mene Pangalos, executive vice president of R&D at AstraZeneca.
The company earlier said AZD7442 only reduced the risk of developing symptoms by 33% among those with confirmed exposure to an infected person.
Get involved!
Comments